Randomized phase II study with window-design to evaluate anti-tumor activity of the survivin antisense oligonucleotide (ASO) ly2181308 in combination with docetaxel for first-line treatment of castrate-resistant prostate cancer (CRPC).
Pawel J. Wiechno
No relevant relationships to disclose
Piotr Chlosta
No relevant relationships to disclose
Joanna Pikiel
No relevant relationships to disclose
Bradley G. Somer
No relevant relationships to disclose
Begoña Mellado
No relevant relationships to disclose
Ignacio Duran Martinez
No relevant relationships to disclose
Daniel E. Castellano
No relevant relationships to disclose
Steffen Wedel
No relevant relationships to disclose
Jose Manuel Cervera Grau
No relevant relationships to disclose
Sophie Callies
Employment or Leadership Position - Lilly
Stock Ownership - Lilly
Valerie Andre
Employment or Leadership Position - Lilly
Stock Ownership - Lilly
Jacqueline Brown
Employment or Leadership Position - Lilly
Stock Ownership - Lilly
Karla Hurt
Employment or Leadership Position - Lilly
Stock Ownership - Lilly
Michael M. F. Lahn
Employment or Leadership Position - Lilly
Stock Ownership - Lilly
Michael Stöckle
No relevant relationships to disclose
Christoph Reuter
No relevant relationships to disclose
Bernhard Heinrich
Research Funding - Lilly